Bristol-Myers Squibb (BMY) has reduced its full-year earnings guidance by about 3%, leading to a 5.1% drop in its stock price amid concerns over patent losses and declining revenue from its oncology drug Revlimid. Despite exceeding analyst expectations with first-quarter earnings of $1.96 per share and total revenues of $11.65 billion, the company's revised outlook has raised alarms for investors, indicating potential revenue losses of $500 million. As Bristol-Myers faces these challenges, analysts will closely monitor its upcoming reports for strategic adjustments and impacts on its long-standing dividend policy.
“Bristol-Myers Squibb (NYSE:BMY) · lowered its full-year earnings guidance · by around 3% · 3%”
“Bristol-Myers Squibb Company · reported · first-quarter 2022 earnings · $1.96 per share”
“Bristol-Myers Squibb Company · beat · Zacks Consensus Estimate · $1.92”
“Bristol-Myers Squibb Company · increased · earnings from year-ago quarter · $1.74”
“Bristol-Myers Squibb Company · total revenues · surpassed Zacks Consensus Estimate · $11.26 billion”
“Bristol-Myers Squibb Company · total revenues · increased from the year-ago period · 5%”
“Bristol Myers · is scheduled to report · quarterly results · before the opening bell”
“Bristol Myers · beat earnings estimates in · two of the last four quarters · with an average surprise of 1.01%”
“Bristol Myers · currently has · an Earnings ESP of · +1.57%”
“Bristol-Myers Squibb Company (NYSE:BMY) · has increased · its dividend yields · for 16 consecutive years”
“Bristol-Myers Squibb Company (NYSE:BMY) · is · a New York-based manufacturer of biopharmaceutical products · true”
“Bristol-Myers Squibb stock · fell · 5.1% · after the drug company lowered its full-year earnings guidance by around 3%”
.svg&width=160)